The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting survivin in cancer
Open accessAbstract
With almost 4,000 citations in Medline in a little over ten years, survivin has certainly kept scores of investigators busy worldwide. Tangible progress has been made in revealing the multiple functions of survivin, uncovering their wirings as integrated cellular networks, and mapping their exploitation in virtually every human tumor, in vivo. Considering the normally long and excruciating timeline of oncology drug discovery, it is clearly a resounding success that a better understanding of survivin biology has led to several clinical trials of survivin-based therapeutics in cancer patients. However, the portfolio of survivin antagonists available in the clinic remains small, pressing the need for a less rigid drug development approach to fully unlock the potential of this unique, albeit unconventional oncology drug target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378
Cited by
Menyhárt, O., Nagy, Á., & Győrffy, B. (2018) · Royal Society Open Science · doi:10.1098/rsos.181006 · Cited by 507
Targeted gene silencing in vivo by platelet membrane–coated metal-organic framework nanoparticles
Zhuang, J., Gong, H., Zhou, J., Zhang, Q., Gao, W., Fang, R. H., & Zhang, L. (2020) · Science Advances · doi:10.1126/sciadv.aaz6108 · Cited by 363
Metadata
- Authors
- Altieri, D. C.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 332
- Issue
- 2
- Pages
- 225-228
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2014199817
- Cited by
- 178
- References
- 1
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting survivin in cancer. https://app.cochat.ai/papers/10.1016/j.canlet.2012.03.005
- The paper
- Altieri, D. C. (2013). Targeting survivin in cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2012.03.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.